BWAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Brainsway Ltd (BWAY) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company shows some positive developments, such as revenue growth and expanding coverage policies, the lack of strong trading signals, mixed technical indicators, and a recent downward price trend suggest waiting for a clearer entry point. The stock's medium- to long-term outlook remains positive, but current conditions do not present an ideal buying opportunity.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near resistance levels (R1: 15.71). The stock's recent price trend shows a -3.04% drop in the regular market, with a slight recovery of 1.96% post-market.
Optum/United Behavioral Health updated its TMS clinical policy, expanding nurse practitioners' roles and improving patient access.
Multiple U.S. payers, including the Department of Veterans Affairs, have adopted similar policies.
Revenue increased by 28.66% YoY in 2025/Q3, and net income grew by 136.56% YoY.
FDA clearance for three indications of the Deep TMS™ platform.
EPS dropped to 0, down -100% YoY.
Gross margin also dropped to 0, down -100% YoY.
Analysts have lowered the price target from $30 to $15, reflecting a change in ADS ratio.
Stock trend analysis suggests a likelihood of further short-term declines (-1.03% in the next week, -1.51% in the next month).
In 2025/Q3, the company demonstrated strong revenue growth (+28.66% YoY) and significant net income growth (+136.56% YoY). However, EPS and gross margin both dropped to 0, indicating profitability challenges.
Analysts maintain a Buy rating but have lowered the price target from $30 to $15 due to a change in the ADS ratio. Positive medium- to long-term outlook is noted, supported by FDA approvals and strategic partnerships.
